Albemarle ALB
Basic Materials · Chemicals - Specialty · Synthos Deep Dive · 2026-07-03
The Overview
Albemarle digs up and refines lithium — the key ingredient in electric-car and phone batteries — plus bromine (flame retardants, oil-and-gas fluids) and some refining catalysts. Think of it as a miner of battery ingredients, not a tech company.
The problem with miners is that they don't set their own prices — the market does. When lithium was booming in 2022–23, Albemarle earned enormous profits. Then lithium prices crashed, and in 2025 the company lost money. Now prices are bouncing back, and the most recent quarter looked much better. So the stock is really a bet on where the lithium price goes next — and nobody, including management, can reliably predict that.
Is the stock cheap or expensive? On this year's expected profits it looks cheap (about 11× earnings) — but those profits only show up if lithium prices stay high, so "cheap" is fragile. Our verdict is Watch: interesting, but too dependent on a commodity price we can't forecast to call it a buy.
Here's what our three scores mean in everyday terms:
- Downside Risk 7/10 (high). The stock swings violently — it fell nearly 60% from its peak, and its fortunes hinge on a commodity price. Financially it's okay (debt is manageable), but the ride is rough.
- Growth Quality 3/10 (low). Profits are lumpy and unpredictable; this is a boom-and-bust business, not a steady grower.
- Exponential Potential 5/10 (moderate). If lithium keeps recovering, profits could multiply fast — but that's out of the company's hands.
The one big worry: if the lithium price rolls back over, the whole earnings story deflates. Everything here is a leveraged bet on one commodity.
Putting a number on it: our fair-value estimate is $145 against a current price of $137.36 — real upside if our numbers are right.
Our summary metrics
Deep cyclicality — lithium-price whipsaw, −58% max drawdown, beta 1.31, FY25 loss, C- letter rating.
Choppy/flat EPS estimates, negative TTM ROE/ROIC, commodity cost-curve moat — not a durable compounder.
Real leverage to a lithium recovery (Q1'26 adj EBITDA +148%) and EV-battery demand — but a price-taker with no reliable acceleration.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Real leverage to a lithium recovery (Q1'26 adj EBITDA +148%) and EV-battery demand — but a price-taker with no reliable acceleration.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $209.75 (high $264 / low $153; 19 Buy · 20 Hold · 6 Sell = Hold) — context, not our anchor |
| Valuation | Trailing EPS negative (FY25 loss) · ~11× FY26E · ~11× FY27E · EV/S 3.1× · EV/EBITDA 22.5× (TTM, depressed) |
| Technicals | Downtrend, near-oversold — $135.56, −37% off 52-wk high, below 50/200-DMA, RSI 30, but +116% 12-mo |
| Conviction | Low — 0 expert voices, 0 KB claims; verdict rests on fundamentals + quant only |
| Position sizing | Watch / small tactical only — 0–2% if you must, sized as a cyclical, not a core hold |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for ALB — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $137.36, 6% above the 50-day average ($130), 12% below the 200-day average ($156) — a mixed trend. 36% below the 52-week high of $216, 89% above the 52-week low of $73.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $137.36 is currently inside the band (band $119–$145).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 57.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.86, positive momentum.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = ALB · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Albemarle (NYSE: ALB), founded 1887 and headquartered in Charlotte, NC, is a global specialty-chemicals producer and the world's largest lithium company. Fiscal year ends December 31. The business is now organized around three reporting lines:
- Energy Storage (lithium) — lithium carbonate, hydroxide and chloride for EV and electronics batteries. This is the swing factor for the entire company.
- Specialties (bromine & lithium specialties) — bromine-based flame retardants, oil-and-gas drilling fluids, tertiary amines, and lithium-specialty reagents; end markets in semiconductors, oil & gas, pharma.
- Ketjen / Corporate (refining catalysts) — in Q1'26 Albemarle sold a controlling stake in Ketjen (and its Eurecat JV) for ~$648M net cash; those earnings are now equity income in Corporate and expected to be immaterial.
Revenue mix (FY2025, from FMP segmentation):
- By segment: Energy Storage $2.71B (53%) · Specialties $1.37B (27%) · Ketjen $1.07B (21%). The lithium segment dominates the P&L and drives virtually all the earnings volatility.
- By geography: FMP's FY2025 geographic file reports only a United States $0.89B line (with the foreign remainder unbroken); FY2024 showed US $0.90B vs Foreign $4.48B — i.e. the revenue base is ~80%+ ex-US, reflecting the global lithium/battery supply chain (heavy Asia/China exposure through the value chain).
The structural story: Albemarle is a commodity price-taker whose profitability is levered to the lithium carbonate equivalent (LCE) price. That is the single most important fact on this page.
2. The expert thesis — (no coverage)
There is no expert coverage of Albemarle in the Synthos knowledge base: total_claims = 0, zero net-bullish voices, zero cautionary voices. None of the tracked expert voices in our panel have made a traceable, dated claim on ALB.
Accordingly, this verdict is entirely fundamentals- and quant-driven — built from FMP financials, analyst estimates, management's own SEC-filed guidance (half-weighted, §9), and the price/technical record. We fabricate no conviction: there are no claim_ids to cite because there are none in the file. Where this note reads cautious, that caution comes from the numbers (deep cyclicality, negative TTM returns on capital, a commodity-price-dependent model), not from an expert panel.
The honest read: absence of KB coverage is itself informative. Our expert panel skews toward secular-growth and quality-compounding theses; a boom-bust commodity chemical simply isn't where they hunt. That's consistent with a Watch, not a conviction Buy.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 7 · High | Deep cyclicality: −58% max drawdown, beta 1.31, an outright FY25 loss (EPS −$5.75), a C- letter rating, and a preferred-stock overhang. Net-debt/EBITDA ~1.1× and a $1.3B debt paydown keep it from an 8. |
| Growth Quality | 3 · Low | Estimates are choppy and flat (~$12 EPS FY26–28E, dipping to $10.6 FY29E); TTM ROE −2.4% / ROIC +2.2%; margins collapsed in 2024–25 and are only now recovering. Commodity cost-curve moat, not a compounder. |
| Exponential Potential | 5 · Moderate | Enormous operating leverage to a lithium recovery (Q1'26 adj EBITDA +148% YoY) and secular EV-battery demand, at a mid-cap $16B. But ALB is a price-taker — the acceleration isn't its to control, so we cap it at mid-scale. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). Because ALB is a cyclical, we anchor on mid-cycle normalized earnings power and a cyclical multiple, and we explicitly map the cases to management's own lithium-price scenarios ($10 / $20 / $30 per kg LCE). We deliberately do not attach probabilities.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Lithium recovers toward ~$30/kg LCE (management's high case → $4.2–4.4B adj EBITDA, $7.5–7.8B sales). Normalized EPS ~$18; the market pays a mid-cycle ~11.5× on peak-ish earnings. | ~$210 (+55%) |
| Base (our anchor) | Lithium holds near the ~$20/kg mid case (management → $2.4–2.6B adj EBITDA, $5.7–6.0B sales). Normalized EPS ~$12 (in line with FY26–28E consensus); a cyclical ~12× multiple. | ~$145 (+7%) |
| Bear | Lithium slides back toward ~$10/kg (management's low case → $0.9–1.0B adj EBITDA, $4.1–4.3B sales). Normalized EPS collapses toward ~$3; the market pays a trough ~11× off depressed EPS plus balance-sheet discount. | ~$70 (−48%) |
Synthos fair value = the base case, ~$145 (+7%), with the full $70–$210 span as the honest range. Note the range is enormous — that width is the thesis: ALB's value is a near-linear bet on the lithium price. Our base sits well below the Street's $209.75 consensus because the Street's targets implicitly assume a sustained higher-price scenario we won't underwrite as a base case. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). ALB is neither a clean compounder nor a self-directed exponential — it's a leveraged cyclical:
- Forward growth: analyst revenue estimates rebuild from the FY25 trough ($5.14B) toward ~$6.4B FY26E, ~$6.7B FY27E, ~$6.9B FY28E — a recovery, not a secular ramp. EPS estimates are flat-to-choppy (~$12.4 FY26E → ~$12.2 FY28E → ~$10.6 FY29E → ~$13.9 FY30E).
- Acceleration (the 2nd derivative): genuinely positive right now off the cycle bottom — Q1'26 revenue +33%, adjusted EBITDA +148%, Energy Storage adj EBITDA +196%. But this is cyclical mean-reversion, not structural acceleration: the estimate path flattens and even dips by FY29E. The 2022→2025 collapse (revenue $9.6B → $5.1B; EPS +$13.41 → −$5.75) is the cautionary mirror image.
- Room to run: at $16B market cap ALB is small enough to multiply if lithium re-rates, and the EV-battery TAM is large and secular. That's the real optionality. But the binding constraint isn't demand — it's price, which ALB does not set.
- Reinvestment runway: capex is being cut to defend cash (FY26E capex $550–600M, roughly flat, down sharply from the $1.7–2.2B build-out years) — a balance-sheet-repair posture, not an expansion story.
Exponential Potential: Moderate (5/10). The upside is real but exogenous — you're betting on the lithium price, with ALB as a high-beta expression of that bet. Own it (if at all) as a tactical cyclical, not a hold-forever exponential.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $5.14B, −4.4% (FY24 $5.38B) — and down 47% from the FY23 peak of $9.62B as lithium prices crashed. FY22 was $7.32B; FY21 just $3.33B. This is the definition of a commodity cycle.
- Quarterly trajectory (the recovery): Q1'25 $1.08B → Q2 $1.33B → Q3 $1.31B → Q4 $1.43B → Q1'26 $1.43B (+33% YoY). The bottom appears to be in.
- Earnings — the volatility: FY25 was an outright loss (operating income +$94M but net income −$510M, bottom-line −$677M, EPS −$5.75) after a −$1.18B FY24. Yet Q1'26 swung to net income $319M ($2.34 diluted / $2.95 adjusted) as pricing recovered. FY23 by contrast earned $13.41 EPS. The swing between years is enormous.
- Margins: gross margin 18.5% TTM (was near-zero in 2024, ~12.5% FY23 peak-cost years) recovering; EBITDA margin 13.6% TTM. Q1'26 adjusted EBITDA margin ~46% shows the operating leverage when price cooperates.
- Cash flow: FY25 operating CF $1.28B, capex −$590M, FCF +$692M — a real improvement after negative FCF in FY23 (−$828M) and FY24 (−$993M) during the build-out. Q1'26 FCF +$248M.
- Balance sheet: cash $1.62B, total debt $3.30B, net debt $1.68B, net-debt/EBITDA ~1.1× TTM. Management paid down $1.3B of debt and lowered its weighted-average rate. Note a $2.24B convertible preferred (issued 2024) carrying ~$167M/yr of preferred dividends — a real claim ahead of common.
6. Valuation — priced in or room?
ALB defies a simple P/E because trailing EPS is negative (the FY25 loss). On forward consensus it looks statistically cheap: ~11× FY26E ($12.37), ~11× FY27E ($12.36), ~11× FY28E ($12.22). EV/Sales is 3.1× and EV/EBITDA is 22.5× TTM — but that TTM EBITDA is depressed; on the mid-cycle ($20/kg) EBITDA of ~$2.5B the EV/EBITDA falls to ~7×, and on the bull ($30/kg) ~$4.3B it's ~4×.
The catch: "cheap on forward EPS" is only true if lithium stays elevated. Those estimates embed a mid-to-high lithium price. If price reverts to the low case, FY26E EPS is nowhere near $12 and the multiple inverts. So the valuation is best read through management's price scenarios (§3), not a single P/E.
Street targets (context): consensus $209.75, high $264, low $153 — the Street is materially more bullish than our $145 base because it credits a durable higher-price scenario. The letter rating is C- (overall score 1/5; DCF, ROE, ROA, P/E all scored 1). Grade split: 19 Buy · 20 Hold · 6 Sell = Hold. Not a value buy; a leveraged bet on the lithium price at a statistically-low-looking multiple.
7. Technicals (from the tech block)
- Trend: down. $135.56 sits below the 50-DMA ($172.24) and the 200-DMA ($148.96) — the 50 is below the 200 region and price is under both (bearish posture). MACD −10.5 (negative).
- Location: −37% off the 52-week high ($215.62) but +107% off the 52-week low ($65.50) — the stock already more than doubled off the bottom, then gave back ground. Max drawdown from peak −58% — a violent name.
- Momentum: RSI(14) 30 — near oversold (<30 line), consistent with the −24% 3-month pullback. No overbought risk; if anything, washed-out short-term.
- Relative strength (mixed): +116% 12-mo vs SPY +21% and QQQ +30% (the cyclical recovery trade), but −24% 3-mo vs SPY +14% / QQQ +22% and −4.5% 6-mo — sharp recent underperformance as lithium and the stock cooled.
- Read: technicals say cyclical, not trending — a huge 12-month recovery now rolling over near-oversold. This is a chart to trade around levels, not a clean uptrend to ride. A base near the 200-DMA / prior support would be a lower-risk tactical entry; strength back above the 50-DMA ($172) would signal the recovery leg resuming.
8. Moat & competitive position
Albemarle's "moat" is a low-cost resource position — world-class brine (Chile/Salar de Atacama via its operations) and hard-rock (Australia) lithium assets, plus scale in bromine where it is a top-two global producer. In commodities, the cost curve is the moat: ALB survives price troughs that bankrupt higher-cost peers. But it is not a pricing-power moat — ALB cannot set the LCE price, and Chinese lithium supply and integrated battery makers exert relentless pressure. Bromine (Specialties) is a steadier, higher-return franchise that partially offsets lithium's volatility, and Q1'26 showed it (Specialties adj EBITDA +30% on firmer bromine pricing).
Peer set (FMP-supplied, market cap): SQM (Sociedad Química y Minera) $20.8B — the closest lithium comp; DuPont $18.9B; LyondellBasell $17.2B; Eastman Chemical $7.9B; Westlake $9.6B; RPM International $14.2B; James Hardie $15.0B; NewMarket $7.2B; Royal Gold $14.2B; Suzano $9.7B. Most are diversified/specialty chemicals; SQM is the only pure lithium comp and the most relevant read-across. ALB's premium-vs-peers rests entirely on whether the lithium cycle turns up.
9. Management, capital allocation & guidance
- Capital allocation (defensive reset): management has pivoted from expansion to balance-sheet repair — capex cut to $550–600M (from $1.7–2.2B in the build years), $1.3B of debt paid down in Q1'26, and non-core divestitures (Ketjen controlling stake + Eurecat JV for ~$648M net). The common dividend (~$1.62/yr, ~1.2% yield) is maintained but the payout ratio is negative on the loss — watch dividend sustainability if the cycle stays low. The 2024 convertible preferred ($2.24B) was a financing-under-duress move that now sits ahead of common.
- Insider activity: the most recent Form 4s (filed 2026-05-19, trades 2026-05-15) show CEO Kent Masters selling ~16.4k shares around $183–184, plus a March gift of ~30.7k shares — sales into the recovery rally. Not a cluster of alarming discretionary distress selling, but no insider buying to signal conviction at these levels either.
- Management's own guidance (SEC 8-K, Q1'26 earnings release, 2026-05-06 — half-weighted; they talk their book): management frames FY2026 as scenario-based on the lithium price: at $10/kg LCE, total-company net sales $4.1–4.3B and adjusted EBITDA $0.9–1.0B; at $20/kg, $5.7–6.0B sales and $2.4–2.6B EBITDA; at $30/kg, $7.5–7.8B sales and $4.2–4.4B EBITDA. They raised the Specialties outlook (net sales $1.3–1.5B, adj EBITDA $225–275M) on firmer bromine pricing, reduced expected interest expense to $120–140M after the debt paydown, guided capex to $550–600M, and reaffirmed $100–150M of cost/productivity savings. CEO Kent Masters: "a strong start to 2026… focused on the things within our control… to enable long-term volume and earnings growth." This guidance is genuine and specific — but note it is explicitly a function of an exogenous price, which is exactly why we anchor conservatively.
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS $3.21, revenue ~$1.59B). The key lines: realized lithium pricing and Energy Storage volumes/EBITDA — does the Q1'26 recovery extend?
- Lithium spot price (the master variable): LCE price trajectory vs the $10/$20/$30 scenario ladder. This single input dominates the thesis.
- Contract book: ~40% of salts volume on long-term agreements — watch price realization vs spot.
- Balance-sheet progress: further debt paydown, FCF sustainability, and any move on the expensive preferred.
- Bromine/Specialties: whether firmer bromine pricing (semis, oil & gas) holds as the steadier earnings ballast.
Thesis tripwires (what would change the call): a decisive lithium-price break below the ~$10/kg low case (→ toward the bear); sustained FCF turning negative again; a dividend cut; or, on the upside, a durable move to the $30/kg high case with two consecutive quarters of Energy Storage EBITDA confirmation (→ upgrade toward Buy — Tactical).
11. Key risks
- Lithium-price cyclicality (structural, the whole ballgame): earnings swing from a −$677M loss (FY25) to $2.7B net income (FY22) on price alone. The stock is a leveraged proxy for one commodity.
- China / oversupply: aggressive Chinese lithium and integrated-battery supply can cap prices for years, as 2024–25 showed.
- Balance-sheet & preferred overhang: manageable net leverage (~1.1×) but a $2.24B convertible preferred sits ahead of common and carries ~$167M/yr in dividends; dividend sustainability is price-dependent.
- Valuation illusion: the "~11× forward" cheapness evaporates if estimates (which embed elevated lithium) miss.
- No expert corroboration: zero KB coverage means no independent conviction layer — the call rests solely on fundamentals/quant, which for a commodity name carry wide error bars.
- Geographic/geopolitical: ~80%+ ex-US revenue and exposure (e.g. the Jordan Bromine JV flooding/Middle-East tensions flagged by management) add operational risk.
12. Verdict, position sizing & monitoring
Watch. Albemarle is a well-run, low-cost leader in a business whose profits it does not control. The Q1'26 rebound (adj EBITDA +148%, net income swinging positive) is real and the balance sheet is being repaired — but with zero expert coverage in our KB, an earnings model that ranges from $0.9B to $4.4B of EBITDA depending on a lithium price nobody can forecast, a C- quant rating, and a stock that already tripled off its low before rolling over, the honest verdict is Watch, not Buy. Our $145 base fair value is only ~7% above the current price and sits far below the Street's $209.75 — the asymmetry isn't compelling enough to underwrite conviction.
- Sizing: Watch / 0–2% tactical only. If expressed at all, size it as a cyclical trade around the lithium cycle and technical levels (near-oversold now), not as a core position. This is a name to buy near cycle-trough pessimism and trim into price recoveries, not to hold blindly.
- Monitoring: re-underwrite on each earnings print and on decisive moves in the LCE price against the scenario ladder; upgrade toward Buy — Tactical only on confirmed, sustained higher-price EBITDA. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $135.56.
- Single biggest risk: the lithium price rolling back over — the entire model is a leveraged bet on one commodity Albemarle cannot control.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert voices cover ALB in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no
claim_ids are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation), and here there is simply nothing to reconcile. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release dated 2026-05-06. Forward figures are analyst consensus (FMP) or management scenarios, labeled as estimates.
- Management caveat: management's guidance (§9) is its own book, half-weighted by design, and is explicitly a function of an exogenous lithium price.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").